A Randomized, Multiple-dose, Multicenter, Comparative Parallel Study to Evaluate the Efficacy, Safety and Pharmacokinetic Characteristics of Intravenous Infusion of Trastuzumab Emtansine (Hetero) and Reference Medicinal Product (Trastuzumab Emtansine, Roche) in Patients of HER2- positive Metastatic breast cancer - TREMBC STUDY
Latest Information Update: 31 Jan 2020
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms TREMBC
- Sponsors Hetero Drugs
Most Recent Events
- 31 Jan 2020 New trial record